Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | SVP, GLOBAL SALES AND SERVICES | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,466 |
Ending reported balance
After 2026-05-18 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-05-18 · Exercise / conversion · Acquired 1,024 · Balance 36,711 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-05-18 · Tax withholding · Disposed 263 · Balance 36,448 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 3 · 2026-05-18 · Exercise / conversion · Acquired 1,473 · Balance 37,921 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 4 · 2026-05-18 · Tax withholding · Disposed 378 · Balance 37,543 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 5 · 2026-05-18 · Exercise / conversion · Acquired 2,416 · Balance 39,959 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 6 · 2026-05-18 · Tax withholding · Disposed 620 · Balance 39,339 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 7 · 2026-05-18 · Exercise / conversion · Acquired 5,551 · Balance 44,890 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 8 · 2026-05-18 · Tax withholding · Disposed 1,424 · Balance 43,466 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,641 |
Reported balance
After 2026-05-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-18 · Exercise / conversion · Disposed 1,024 · Balance 5,641 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 16,209 |
Reported balance
After 2026-05-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-05-18 · Exercise / conversion · Disposed 1,473 · Balance 16,209 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 41,089 |
Reported balance
After 2026-05-18 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-05-18 · Exercise / conversion · Disposed 2,416 · Balance 41,089 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 127,675 |
Reported balance
After 2026-05-18 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-05-18 · Exercise / conversion · Disposed 5,551 · Balance 127,675 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter, until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter.
F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested.
F6: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter, until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2025 Filed Mar 12, 2025 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,946 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007890 · form4-03122025_090353.xml · derivative · entry 6 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,521 Underlying: Common Stock · 2,946 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007890 · form4-03122025_090353.xml · derivative · entry 5 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,810 Underlying: Common Stock · 2,049 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,148 | $4.36 | $5,005.28 |
DisclosureSEC source: 0001415889-25-007890 · form4-03122025_090353.xml · nonDerivative · entry 4 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,919 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 10, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,946 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-007890 · form4-03122025_090353.xml · nonDerivative · entry 3 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 799 | $4.36 | $3,483.64 |
DisclosureSEC source: 0001415889-25-007890 · form4-03122025_090353.xml · nonDerivative · entry 2 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,121 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 10, 2025, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 21:53 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,049 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-007890 · form4-03122025_090353.xml · nonDerivative · entry 1 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 58,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-007280 · form4-03062025_100338.xml · derivative · entry 2 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,004 Underlying: Common Stock · 58,004 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2026 and each March 10 thereafter, until fully vested. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 22:52 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (right to buy) · Derivative | 91,911 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001415889-25-007280 · form4-03062025_100338.xml · derivative · entry 1 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,911 Underlying: Common Stock · 91,911 shares Expires 2035-03-04 F1 · derivative.exercise_date: The shares subject to the option shall vest over 4 years with 1/48 of the total shares underlying the option vesting on April 4, 2025 and each month thereafter until fully vested. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:25 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027369 · form4-11202024_111129.xml · derivative · entry 6 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,467 Underlying: Common Stock · 2,210 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:25 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027369 · form4-11202024_111129.xml · derivative · entry 5 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,859 Underlying: Common Stock · 1,536 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:25 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 861 | $6.03 | $5,191.83 |
DisclosureSEC source: 0001415889-24-027369 · form4-11202024_111129.xml · nonDerivative · entry 4 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,871 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:25 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,210 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027369 · form4-11202024_111129.xml · nonDerivative · entry 3 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:25 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 599 | $6.03 | $3,611.97 |
DisclosureSEC source: 0001415889-24-027369 · form4-11202024_111129.xml · nonDerivative · entry 2 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,522 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:25 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,536 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-027369 · form4-11202024_111129.xml · nonDerivative · entry 1 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021854 · form4-08212024_100852.xml · derivative · entry 6 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,677 Underlying: Common Stock · 2,210 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021854 · form4-08212024_100852.xml · derivative · entry 5 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,395 Underlying: Common Stock · 1,536 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 861 | $5.53 | $4,761.33 |
DisclosureSEC source: 0001415889-24-021854 · form4-08212024_100852.xml · nonDerivative · entry 4 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,585 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,210 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021854 · form4-08212024_100852.xml · nonDerivative · entry 3 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 599 | $5.53 | $3,312.47 |
DisclosureSEC source: 0001415889-24-021854 · form4-08212024_100852.xml · nonDerivative · entry 2 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,236 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 19, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 22:15 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,536 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021854 · form4-08212024_100852.xml · nonDerivative · entry 1 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:28 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 1,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014144 · form4-05222024_100536.xml · derivative · entry 6 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,887 Underlying: Common Stock · 1,473 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:28 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 6,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-014144 · form4-05222024_100536.xml · derivative · entry 5 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,931 Underlying: Common Stock · 6,659 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the Restricted Stock Units (the "RSU Award") shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. F3 · derivative.expiration_date: The shares subject to the Restricted Stock Units (the "RSU Award") shall vest over four years with 13/48 of the total shares underlying the RSU Award vesting on May 18, 2024; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter; and 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:28 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 574 | $5.96 | $3,421.04 |
DisclosureSEC source: 0001415889-24-014144 · form4-05222024_100536.xml · nonDerivative · entry 4 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,299 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:28 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 1,473 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014144 · form4-05222024_100536.xml · nonDerivative · entry 3 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:28 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,594 | $5.96 | $15,460.24 |
DisclosureSEC source: 0001415889-24-014144 · form4-05222024_100536.xml · nonDerivative · entry 2 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,400 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:28 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 6,659 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-014144 · form4-05222024_100536.xml · nonDerivative · entry 1 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 20, 2024 Filed Mar 21, 2024 22:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 5,464 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008881 · form4-03212024_100334.xml · derivative · entry 3 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,464 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award vested on March 20, 2024. F3 · derivative.expiration_date: The shares subject to the RSU Award vested on March 20, 2024. Read SEC document |
| March 20, 2024 Filed Mar 21, 2024 22:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 2,129 | $6.70 | $14,264.30 |
DisclosureSEC source: 0001415889-24-008881 · form4-03212024_100334.xml · nonDerivative · entry 2 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,335 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 20, 2024 Filed Mar 21, 2024 22:19 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 5,464 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-008881 · form4-03212024_100334.xml · nonDerivative · entry 1 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 23:46 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 35,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007436 · form4-03082024_110313.xml · derivative · entry 2 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,360 Underlying: Common Stock · 35,360 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 23:46 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (right to buy) · Derivative | 52,631 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001415889-24-007436 · form4-03082024_110313.xml · derivative · entry 1 Busque Philippe · CIK 0001991396 · SVP, GLOBAL SALES AND SERVICES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,631 Underlying: Common Stock · 52,631 shares Expires 2034-03-06 F1 · derivative.exercise_date: The shares subject to the option shall vest over 4 years with 1/48 of the total shares underlying the option vesting on April 6, 2024 and each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.